For example, in a systematic review and meta-analysis study on NSCLC, it was found that the combination therapy of PD-1/PD-L1 inhibitors and radiotherapy can improve the OS, PFS, and tumor response rate of advanced NSCLC patients without increasing serious adverse events 178. Here, PDCD1 is linked to non-small cell lung carcinoma.